- Gilead Sciences (GILD +0.5%) downgraded to Equal Weight from Overweight by Morgan Stanley. Price target maintained at $127 (27% upside).
- Valeant Pharmaceuticals (VRX +3.3%) downgraded to Equal Weight from Overweight by Morgan Stanley. Price target lowered to $200 (14% upside) from $284.
- Mead Johnson (MJN +0.7%) downgraded to Underperform from Neutral by BofA Merrill Lynch. Price target lowered to $78 (7% upside) from $80.
- Ilumina (ILMN +1.9%) downgraded to Neutral from Buy by Mizuho Securities. Price target lowered to $150 (5% upside) from $250.
- Chimerix (CMRX +1.7%) downgraded to Equal Weight from Overweight by Morgan Stanley. Price target lowered to $50 (34% upside) from $56.
- Regeneron Pharmaceuticals (REGN +0.6%) downgraded to Equal Weight from Overweight with a price target of $593 (20% upside) by Morgan Stanley.
- Diplomat Pharmacy (DPLO +1.1%) downgraded to Equal Weight from Overweight by Morgan Stanley. Price target lowered to $31 (24% upside) from $58.
- AmerisourceBergen (ABC -0.3%) downgraded to Equal Weight from Overweight by Morgan Stanley. Price target lowered to $93 (0% upside) from $120.